Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle - European Medical Journal

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle

Download PDF
*Maria A.V. Marzolini, Sergio A. Quezada, Karl S. Peggs

No potential conflict of interest.

EMJ Oncol. ;3[1]:70-76. DOI/10.33590/emjoncol/10314057.
Cancer immunotherapy, cytotoxic T lymphocyte associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1).

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Manipulating the complex interaction between the immune system and tumour cells has been the focus of cancer research for many years, but it is only in the past decade that significant progress has been made in the field of cancer immunotherapy resulting in clinically effective treatments. The blockade of co-inhibitory immune checkpoints, essential for maintaining lymphocyte homeostasis and self-tolerance, by immunomodulatory monoclonal antibodies has resulted in the augmentation of anti-tumour responses. The greatest successes so far have been seen with the blockade of cytotoxic T lymphocyte associated antigen-4, which has resulted in the first Phase III clinical trial showing an overall survival benefit in metastatic melanoma, and in the blockade of the programmed cell death protein-1 axis. This concise review will focus on the clinical advances made by the blockade of these two pathways and their role in current cancer treatment strategies.

Please view the full content in the pdf above.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally